Contact

• workRespiratory Medicine Unit, David Evans Centre
  Nottingham City Hospital
  Hucknall Road
  Nottingham
  NG5 1PB
  UK
• work01159691169 57462
• David.Baldwin@nottingham.ac.uk

Biography

David Baldwin works as a consultant respiratory physician sub-specialising in lung cancer and mesothelioma and interventional procedures. He is Chair of the Clinical Expert Group for Lung Cancer, NHS England and Clinical Director of the East Midlands Cancer Alliance. He is Honorary Professor in the School of Medicine at the University of Nottingham. He has obtained research grants from a variety of charities and NIHR. His primary research interests are in CT screening and lung cancer epidemiology. He is lead respiratory physician on the UK CT lung cancer screening trial (UKLS). He has published over 190 papers. He has held the positions of Honorary Secretary of the British Thoracic Society, Clinical Lead on the NICE Lung Cancer Guideline Development Group and Chair of the Quality Standards Group on Lung Cancer. He works with Public Health England and the National Cancer Research Institute and is Chair of the Screening Prevention and Early Diagnosis Group. He enjoys time with his family and is a keen windsurfer and advanced instructor.

Expertise Summary

Overview

I completed 11 years of post-graduate training and became accredited in general medicine and respiratory medicine in 1996. As a consultant, I practised general (internal) medicine and respiratory medicine until 2011 and now limit this to respiratory medicine. I am based at Nottingham University Hospitals (City Campus). I have experience in all areas of respiratory medicine and have a special interest in lung cancer, pleural disease, and interventional bronchoscopy and thoracoscopy.

Continuing Professional Development

I have registered and completed the CPD record for the Royal College of Physicians since its inception. I continue to comply with CPD requirements with local, national, and international educational activities. As part of my CPD I have attended local courses on counselling (level 1-3), equal opportunities, leading and managing change, teaching improvement, senior management training, Clinical Tutor training, mandatory Trust training, National Cancer Action Team Advanced Communication skills course and Good Clinical Practice (research).

RESEARCH

Overview

I have a broad-based background in medical research, encompassing aspects of asthma pathophysiology, epidemiology, occupational asthma, pulmonary infection, cystic fibrosis, information technology in medicine, lung cancer and a number of smaller projects.

Lung Cancer Research

Over the last 7 years my main research focus has been on lung cancer. I am now involved with a number of important research projects that link with some of my external, national duties.

Screening for Lung Cancer

I am co-applicant and lead respiratory physician on a large national study on CT screening for lung cancer (UK Lung Screen) funded by the NIHR HTA programme. This has just completed the pilot study that has recruited 4000 subjects. There is likely to be considerable benefit in screening for lung cancer and this study will help the design of cost effective programmes. I am coapplicant on a lung cancer screening trial at UCL looking at aspects of recruitment of the hard to reach. I am also co-applicant in the Yorkshire Screening Trial (funded for £5.2 million)

Epidemiology and Health Services Research

I have been working in collaboration with Professor Richard Hubbard, Division of Epidemiology and Public Health on a number of projects employing large datasets to answer some key questions. This involves the co-supervision of one DM and 3 PhD Fellows. I also provide clinical training. This has resulted in a number of successful grant applications and several publications. This working is now look at all aspects of the lung cancer pathway and the research team is growing to include more members of the multidisciplinary team. Nottingham now has a national reputation for its contribution to research in this area.

Other lung cancer research

I am an investigator in a number of studies including MesoVATS, Fragmatic and BOOST all funded by non-pharma sources. I have an active role on research design and steering committees. Three recent examples are: Prophylactic radiotherapy in Tracts (mesothelioma) - successful funding based at Christie Hospital Manchester; Surgery or SABR for patients with borderline fitness (re-application in progress); and Early palliative care in lung cancer (unsuccessful; high rating by HTA). I have also been involved in studies of biomarkers in lung cancer. I am principal investigator for NUH on the Sputnik trial and SABRTooTH trials.

Teaching Summary

I have been actively involved in teaching and training at undergraduate and postgraduate level. In the latter I have held a number of posts at regional and national level including advice to… read more

Research Summary

Epidemiology of lung cancer

Diagnostic and staging clinical pathways in lung cancer

Early diagnosis of lung cancer

CT screening for lung cancer

Selected Publications

• BALDWIN DR, HANSELL DM, DUFFY SW and FIELD JK, 2014. Lung cancer screening with low dose computed tomography. BMJ (Clinical research ed.). 348, g1970
• POWELL HA, IYEN-OMOFOMAN B, HUBBARD RB, BALDWIN DR and TATA LJ, 2013. The association between smoking quantity and lung cancer in men and women. Chest. 143(1), 123-9
• BALDWIN DR, WHITE B, SCHMIDT-HANSEN M, CHAMPION AR, MELDER AM and GUIDELINE DEVELOPMENT GROUP, 2011. Diagnosis and treatment of lung cancer: summary of updated NICE guidance. BMJ (Clinical research ed.). 342, d2110
• BALDWIN, D. R., DUFFY, S. W., WALD, N. J., PAGE, R., HANSELL, D. M. and FIELD, J. K., 2010. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer THORAX. 66(4), 308-313

• View all publications

I have been actively involved in teaching and training at undergraduate and postgraduate level. In the latter I have held a number of posts at regional and national level including advice to government.

Undergraduate

I teach CP3 and CP 5 medical students for an hour each week. I lecture on the CP5 programme. Between 1996 and 2001 I sat on the Medical and Surgical Working Party, a working group supporting the Curriculum Committee. I have previously mentored student and have promoted respiratory medicine at several student careers events. I am a contact for careers advice in the student handbook.

Postgraduate

I held the post of RCP District Tutor (College Tutor) from 1997 to 2002 and during this time developed a regular system of protected education sessions covering a general medical curriculum (similar to the now well-established Core Medical Training curriculum). I also created a new training programme for PACES. During this time and after, I hosted the PACES examination at NUH. I lectured at the RCP and at several hospitals on the development of a teaching programme for SHOs. I became assistant regional advisor in 1999 and continued until 2002.

I became Director of Postgraduate Medical Education in 2003 and continued until 2009. During this time I redeveloped the support system provide by the education centre in line with the national development in education including the need for more support for educational supervision and formalised teaching. I wrote the first (in the country) Trust Strategy for Postgraduate Medical Education and this was used as a template at several other NHS Trusts. I became Chair of the regional Clinical Tutors and Medical Education Managers in 2004 and continued until 2009. I was a council member on the National Association of Clinical Tutors and in this role was involved in several advisory roles involving the Department of Health. I was an active member of several Deanery based committees (see committees below).

I developed several teaching courses including teaching days on respiratory medicine, interventional bronchoscopy and lung cancer. As College Tutor I developed an acute medicine course and since then NUH became of the first sites to offer the Federation of Colleges of Physicians and Anaesthetists accredited course "IMPACT" (Ill Medical Patient Acute Care and Treatment) RCP and RCS accredited. I made contributions to the written material and am acknowledged in the manual. I now direct 1 to 2 courses per year and run 1 to 2 instructor training courses per year.

Supervision

I provide educational and clinical supervision to junior doctors at all levels. At any one time the amounts to 1 to 3 foundation doctors, 2 core medical training and one registrar. I also co-supervise 3 PhD students and was co-supervisor to three students one who obtained a DM from the University of Nottingham and two who obtained PhDs. My supervisory role includes research supervision and advanced clinical and management training.

National and Local Duties to Support Lung Cancer and Respiratory Medicine

I have a number of key roles that fit with my overall aim to improve the care of lung cancer patients and respiratory patients in general.

I am Chair of the Clinical Reference Group for Lung cancer for NHS England (2014- ). This is the key advisory group to NHSE and has been responsible for producing the service specification for lung cancer. The group advised NHS England on all matters relating to lung cancer. The group has an important role in providing expert advice to the CRUK/Macmillan ACE programme.

I am Lead for the East Midlands Strategic Clinical Network Lung Cancer Expert Clinical Advisory Group. This role involves regional implementation of best practice through implementation of guidelines, audit and research.

I was Honorary Secretary to the British Thoracic Society (BTS from 2009-13). This position involved supporting the important role of the BTS and brought me into contact with policy makers in the Department of Health.

I attended a variety of committees including the DH advisory Group on lung cancer and mesothelioma, Lung Cancer Awareness Month and was Chair of the BTS Lung Cancer and Mesothelioma Specialist Advisory Group for 4 years until December 2009. The latter has proved an influential group. It has overseen the production of the BTS Mesothelioma Statement and the forth-coming BTS guidelines for fitness for radical treatment as well as commenting on numerous documents. As Chair I have been involved with much of the work.

I support the work of an NHS Improvement Foundation Pilot (that was discussed at meetings I attended at the DH at an early stage) in Nottingham that is training volunteers to teach others about awareness of early symptoms of lung, breast and bowel cancer. I am on the steering group and run workshops (both in Nottingham and other pilots).

I am a member of the National Cancer Research Institute (NCRI) lung Cancer Group and the Screening Prevention and Early Diagnosis Group (set up in 2012). Both of these groups are influential in planning and supporting lung cancer and cancer research.

NATIONAL INSTITUTE FOR HEALTH AN CLINICAL EXCELLENCE

I was Clinical Lead in the NICE management of Lung Cancer Guideline Update, published in April 2011. The guideline was well received. Subsequently I chaired the NICE quality standard Topic expert Group and the Standard was published in March 2012. Draft Commissioning Outcomes Framework indicators have now been submitted to NICE. This has been an excellent opportunity to work with committed colleagues to encourage better standards of care for lung cancer. As a busy clinician, I have found it easy to prioritise subjects into those most likely to make the most difference.

I was a NICE Fellow from 2012 to 2015, which allowed me to learn more about the process of implementation and the growing science behind it. This has enabled me to encourage the commissioning of services that can deliver the standards that have been set.

Past Research

United Kingdom Lung Cancer CT Screening Study (UKLS).

Feasibility Study

Pilot Study

£256000

£2.2M

NIHR HTA, 2010-11

NIHR HTA, 2011-2014

Co-applicant

Co-applicant

Analysis of the National Lung Cancer Audit

(to host a DM Fellow with Prof Hubbard)

£150000

Royal College of

Physicians, 2009-2011

Principal applicant

Analysis of multiple datasets to look at aspects of risk of death from lung cancer

£150000

University of Nottingham Biomedical Research

Unit 2011-2013

Co-applicant

Analysis of factors predicting emergency admission to hospitals and outcome.

£150000

Roy Castle Foundation 2013-2016

Co-applicant

Prophylactic Irradiation of Tracts

£243211

Christie Hospital (RFPB) 2012-PB-PG-1010-23232

Co-applicant

Pilot study of metabolomics biomarkers

£9800

NUH NHS R&D 2009-

Principal applicant

Developing and testing targeted invitation materials to increase uptake of lung cancer screening in communities at high risk of lung cancer

£288000

National Awareness and Early Diagnosis Initiative April 2014-

Co-applicant

A study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic Ablative Radiotherapy (SABR) with surgery in paTients with peripheral stage I nOn-small cell lung cancer (NSCLC) cOnsidered To be at Higher risk of complications from surgical resection.

£246179

National Institute for Health Research (NIHR)

Research for Patient Benefit (RfPB) [PB-PG-0613-31114] August 2014-

Project Title

Grant Status (Asc)

Primary Staff Contact

Total Issued

Start Date

26388

Nottingham University Hospitals NHS Trust

SELECT Selection of Eligible People for Lung Cancer Screening using Electronic Primary Care DaTa: Development of new risk prediction models

£358,737.23

01-Jun-18

Principal Applicant

Co-applicant

Future Research

Yorkshire Lung Cancer Screening Trial

£5.2M

Yorkshire Cancer

2017- 2022

Co-applicant

Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway (radioX)

£113,754.82

CRUK Early Diagnosis Advisory Group

2017- 2019

Co- PI

Artificial Intelligence and Big Data for Early Lung Cancer Diagnosis

£1.6M

National Institute for Health Research (NIHR)

Invention for Innovation (i4i) 2017-

Co-applicant

FaHRAS Cancer Risk Assessment Software

94,000

SBRI

Co-applicant

The effect of adding a personalised smoking cessation intervention to a lung cancer screening programme.

£911,720

Yorkshire Cancer

2018- 2022

Co-applicant

Methods for prevention and early detection of lung cancer after Hodgkin-lymphoma treatment

£78,327

Roy Castle Lung Cancer Foundation

April 2020-22

Co-applicant

Impact on Quality of life from multi-modality treatment for lung cancer: A randomised controlled feasibility trial of surgery versus radiotherapy in addition to systemic anti-cancer therapy in potentially resectable Stage III-N2 NSCLC

£249,970.

NIHR RFPB

PB-PG-1217-20039

2019-22

Co-applicant

PI local

Readiness of lung cancer screening services to deliver concurrent smoking cessation treatment: Guideline and implementation toolkit development

£73,943.59

CRUK Tobacco Advisory Group - Project Award C63992/A27905

Co-applicant

4-in-the-Lung-Run

Euro 7,999,787

Horizon 2020

Co-applicant, PI Local

The integration and analysis of data using artificial intelligence to improve patient outcomes with thoracic diseases (DART)

£11,286,784

Innovate UK

Co-applicant

PI Local

DOLCE: Determining the impact of Optellum's Lung Cancer Prediction (LCP) artificial

intelligence solution for lung nodule risk stratification on service utilisation, health

Economics and patient outcomes

NIHR Artificial Intelligence

£1,479,044

Chief Investigator / Principal applicant

2021 - 2023

AI assisted Chest X-ray triage for improving diagnostic efficiency and early detection of Lung cancer

SBRI Healthcare Cancer Programme

£3,208,661

Chief Investigator

2021-2024

• JALLOW, M., BLACK, G., VAN OS, S., BALDWIN, D. R., BRAIN, K. E., DONNELLY, M., JANES, S. M., KURTIDU, C., MCCUTCHAN, G., ROBB, K. A., RUPAREL, M. and QUAIFE, S. L., 2022. Acceptability of a standalone written leaflet for the National Health Service for England Targeted Lung Health Check Programme: A concurrent, think-aloud study: Health Expect Health Expect. 25(4), 1776-1788
• ARAGHI, M., FIDLER-BENAOUDIA, M., ARNOLD, M., RUTHERFORD, M., BARDOT, A., FERLAY, J., BUCHER, O., DE, P., ENGHOLM, G., GAVIN, A., KOZIE, S., LITTLE, A., MOLLER, B., ST JACQUES, N., TERVONEN, H., WALSH, P., WOODS, R., O'CONNELL, D. L., BALDWIN, D., ELWOOD, M., SIESLING, S., BRAY, F., SOERJOMATARAM, I., ICBP SURVMARK- LOCAL LEADS, ICBP SURVMARK- ACADEMIC REFERENCE GROUP, ICBP CLINICAL COMMITTEE-LUNG, ICBP SURVMARK-2 ACADEMIC REFERENCE GROUPICBP SURVMARK-2 ACADEMIC REFERENCE GROUP and ICBP CLINICAL COMMITTEE - LUNGICBP CLINICAL COMMITTEE - LUNG, 2022. International differences in lung cancer survival by sex, histological type and stage at diagnosis: an ICBP SURVMARK-2 Study: Thorax Thorax. 77(4), 378-390
• BURZIC, A., O'DOWD, E. L. and BALDWIN, D. R., 2022. The Future of Lung Cancer Screening: Current Challenges and Research Priorities: Cancer Manag Res Cancer Manag Res. 14, 637-645
• CROSBIE, P. A. J., GABE, R., SIMMONDS, I., HANCOCK, N., ALEXANDRIS, P., KENNEDY, M., ROGERSON, S., BALDWIN, D., BOOTON, R., BRADLEY, C., DARBY, M., ECKERT, C., FRANKS, K. N., LINDOP, J., JANES, S. M., MOLLER, H., MURRAY, R. L., NEAL, R. D., QUAIFE, S. L., UPPERTON, S., SHINKINS, B., THARMANATHAN, P. and CALLISTER, M. E. J., 2022. Participation in community-based lung cancer screening: the Yorkshire Lung Screening Trial: Eur Respir J Eur Respir J.
• GROVES, S., MCCUTCHAN, G., QUAIFE, S. L., MURRAY, R. L., OSTROFF, J. S., BRAIN, K., CROSBIE, P. A. J., YORKE, J., BALDWIN, D., FIELD, J. K. and MCWILLIAMS, L., 2022. Attitudes towards the integration of smoking cessation into lung cancer screening in the United Kingdom: A qualitative study of individuals eligible to attend: Health Expect Health Expect. 25(4), 1703-1716
• HALL, H., RUPAREL, M., QUAIFE, S. L., DICKSON, J. L., HORST, C., TISI, S., BATTY, J., WOZNITZA, N., AHMED, A., BURKE, S., SHAW, P., SOO, M. J., TAYLOR, M., NAVANI, N., BHOWMIK, A., BALDWIN, D. R., DUFFY, S. W., DEVARAJ, A., NAIR, A. and JANES, S. M., 2022. The role of computer-assisted radiographer reporting in lung cancer screening programmes: Eur Radiol Eur Radiol.
• JALLOW, M., BLACK, G., VAN OS, S., BALDWIN, D. R., BRAIN, K. E., DONNELLY, M., JANES, S. M., KURTIDU, C., MCCUTCHAN, G., ROBB, K. A., RUPAREL, M. and QUAIFE, S. L., 2022. Acceptability of a standalone written leaflet for the National Health Service for England Targeted Lung Health Check Programme: A concurrent, think-aloud study: Health Expect Health Expect. 25(4), 1776-1788
• MORGAN, H., BALDWIN, D., HUBBARD, R., NAVANI, N., WEST, D. and O'DOWD, E. L., 2022. Ninety-day mortality following lung cancer surgery: outcomes from the English national clinical outcomes audit: Thorax Thorax. 77(7), 724-726
• NAVANI, N., BALDWIN, D. R., EDWARDS, J. G., EVISON, M., MCDONALD, F., NICHOLSON, A. G., FENEMORE, J., SAGE, E. K. and POPAT, S., 2022. Lung Cancer in the United Kingdom: J Thorac Oncol J Thorac Oncol. 17(2), 186-193
• O'DOWD, E. L., TEN HAAF, K., KAUR, J., DUFFY, S. W., HAMILTON, W., HUBBARD, R. B., FIELD, J. K., CALLISTER, M. E., JANES, S. M., DE KONING, H. J., RAWLINSON, J. and BALDWIN, D. R., 2022. Selection of eligible participants for screening for lung cancer using primary care data: Thorax Thorax. 77(9), 882-890
• ROBBINS, H. A., CHEUNG, L. C., CHATURVEDI, A. K., BALDWIN, D. R., BERG, C. D. and KATKI, H. A., 2022. Management of Lung Cancer Screening Results Based on Individual Prediction of Current and Future Lung Cancer Risks: J Thorac Oncol J Thorac Oncol. 17(2), 252-263
• WAIT, S., ALVAREZ-ROSETE, A., OSAMA, T., BANCROFT, D., CORNELISSEN, R., MARUSIC, A., GARRIDO, P., ADAMEK, M., VAN MEERBEECK, J., SNOECKX, A., LELEU, O., HULT, E. H., COURAUD, S. and BALDWIN, D. R., 2022. Implementing Lung Cancer Screening in Europe: Taking a Systems Approach: JTO Clin Res Rep JTO Clin Res Rep. 3(5), 100329
• BALATA, H., RUPAREL, M., O'DOWD, E., LEDSON, M., FIELD, J. K., DUFFY, S. W., QUAIFE, S. L., SHARMAN, A., JANES, S., BALDWIN, D., BOOTON, R. and CROSBIE, P. A. J., 2021. Analysis of the baseline performance of five UK lung cancer screening programmes: Lung Cancer Lung Cancer. 161, 136-140
• BALDWIN, D. R., BRAIN, K. and QUAIFE, S., 2021. Participation in lung cancer screening: Transl Lung Cancer Res Transl Lung Cancer Res. 10(2), 1091-1098
• BALDWIN, D. R., CALLISTER, M. E., CROSBIE, P. A., O'DOWD, E. L., RINTOUL, R. C., ROBBINS, H. A. and STEELE, R. J. C., 2021. Biomarkers in lung cancer screening: the importance of study design: Eur Respir J Eur Respir J. 57(1),
• FIELD, J. K., VULKAN, D., DAVIES, M. P. A., BALDWIN, D. R., BRAIN, K. E., DEVARAJ, A., EISEN, T., GOSNEY, J., GREEN, B. A., HOLEMANS, J. A., KAVANAGH, T., KERR, K. M., LEDSON, M., LIFFORD, K. J., MCRONALD, F. E., NAIR, A., PAGE, R. D., PARMAR, M. K. B., RASSL, D. M., RINTOUL, R. C., SCREATON, N. J., WALD, N. J., WELLER, D., WHYNES, D. K., WILLIAMSON, P. R., YADEGARFAR, G., GABE, R. and DUFFY, S. W., 2021. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis: Lancet Reg Health Eur Lancet Reg Health Eur. 10, 100179
• JALLOW, M., BONFIELD, S., KURTIDU, C., BALDWIN, D. R., BLACK, G., BRAIN, K. E., DONNELLY, M., JANES, S. M., MCCUTCHAN, G., ROBB, K. A., RUPAREL, M., VAN OS, S. and QUAIFE, S. L., 2021. Decision Support Tools for Low-Dose CT Lung Cancer Screening: A Scoping Review of Information Content, Format, and Presentation Methods: Chest Chest.
• JONES, G. S., KHAKWANI, A., PASCOE, A., FOWERAKER, K., MCKEEVER, T. M., HUBBARD, R. B. and BALDWIN, D. R., 2021. Factors associated with survival in small cell lung cancer: an analysis of real-world national audit, chemotherapy and radiotherapy data: Ann Palliat Med Ann Palliat Med. 10(4), 4055-4068
• MORGAN, H., ELLIS, L., O'DOWD, E. L., MURRAY, R. L., HUBBARD, R. and BALDWIN, D. R., 2021. What is the Definition of Cure in Non-small Cell Lung Cancer?: Oncol Ther Oncol Ther. 9(2), 365-371
• ROBBINS, H. A., ALCALA, K., SWERDLOW, A. J., SCHOEMAKER, M. J., WAREHAM, N., TRAVIS, R. C., CROSBIE, P. A. J., CALLISTER, M., BALDWIN, D. R., LANDY, R. and JOHANSSON, M., 2021. Correction: Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom: Br J Cancer Br J Cancer. 125(2), 305
• ROBBINS, H. A., ALCALA, K., SWERDLOW, A. J., SCHOEMAKER, M. J., WAREHAM, N., TRAVIS, R. C., CROSBIE, P. A. J., CALLISTER, M., BALDWIN, D. R., LANDY, R. and JOHANSSON, M., 2021. Comparative performance of lung cancer risk models to define lung screening eligibility in the United Kingdom: Br J Cancer Br J Cancer. 124(12), 2026-2034
• SANDS, J., TAMMEMAGI, M. C., COURAUD, S., BALDWIN, D. R., BORONDY-KITTS, A., YANKELEVITZ, D., LEWIS, J., GRANNIS, F., KAUCZOR, H. U., VON STACKELBERG, O., SEQUIST, L., PASTORINO, U. and MCKEE, B., 2021. Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation: J Thorac Oncol J Thorac Oncol. 16(1), 37-53
• TAYLOR, S., YORKE, J., TSIM, S., NAVANI, N., BALDWIN, D., WOOLHOUSE, I., EDWARDS, J., GRUNDY, S., ROBSON, J., RHODES, S., GOMES, F., BLACKHALL, F., FAIVRE-FINN, C. and EVISON, M., 2021. Impact on quality of life from multimodality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multimodality treatment in potentially resectable stage III-N2 NSCLC (the PIONEER trial): BMJ Open Respir Res BMJ Open Respir Res. 8(1),
• JONES GS, ELIMIAN K, BALDWIN DR, HUBBARD RB and MCKEEVER TM, 2020. A systematic review of survival following anti-cancer treatment for small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 141, 44-55
• BALDWIN DR, GUSTAFSON J, PICKUP L, ARTETA C, NOVOTNY P, DECLERCK J, KADIR T, FIGUEIRAS C, STERBA A, EXELL A, POTESIL V, HOLLAND P, SPENCE H, CLUBLEY A, O'DOWD E, CLARK M, ASHFORD-TURNER V, CALLISTER ME and GLEESON FV, 2020. External validation of a convolutional neural network artificial intelligence tool to predict malignancy in pulmonary nodules. Thorax. 75(4), 306-312
• MORGAN, HELEN, O'DOWD, EMMA L., NAIR, ARJUN and BALDWIN, DAVID R., 2020. New fissure-attached nodules in lung cancer screening: more practical implications from the NELSON study? Comment TRANSLATIONAL LUNG CANCER RESEARCH. 9(5), 2161-2164
• AU-YONG, I. T. H., HAMILTON, W., RAWLINSON, J. and BALDWIN, D. R., 2020. Pulmonary nodules BMJ-BRITISH MEDICAL JOURNAL. 371,
• KHAKWANI, A., HARDEN, S., BECKETT, P., BALDWIN, D., NAVANI, N., WEST, D. and HUBBARD, R., 2020. Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England: Thorax Thorax. 75(3), 237-243
• MORGAN, H., O'DOWD, E. L., NAIR, A. and BALDWIN, D. R., 2020. New fissure-attached nodules in lung cancer screening: more practical implications from the NELSON study?: Transl Lung Cancer Res Transl Lung Cancer Res. 9(5), 2161-2164
• MURRAY, R. L., BRAIN, K., BRITTON, J., QUINN-SCOGGINS, H. D., LEWIS, S., MCCUTCHAN, G. M., QUAIFE, S. L., WU, Q., ASHURST, A., BALDWIN, D., CROSBIE, P. A. J., NEAL, R. D., PARROTT, S., ROGERSON, S., THORLEY, R. and CALLISTER, M. E., 2020. Yorkshire Enhanced Stop Smoking (YESS) study: a protocol for a randomised controlled trial to evaluate the effect of adding a personalised smoking cessation intervention to a lung cancer screening programme: BMJ Open BMJ Open. 10(9), e037086
• QUAIFE, S. L., RUPAREL, M., DICKSON, J. L., BEEKEN, R. J., MCEWEN, A., BALDWIN, D. R., BHOWMIK, A., NAVANI, N., SENNETT, K., DUFFY, S. W., WALLER, J. and JANES, S. M., 2020. Reply to Wilson: Improving Lung Cancer Screening Uptake: Am J Respir Crit Care Med Am J Respir Crit Care Med. 202(8), 1193-1194
• QUAIFE, S. L., RUPAREL, M., DICKSON, J. L., BEEKEN, R. J., MCEWEN, A., BALDWIN, D. R., BHOWMIK, A., NAVANI, N., SENNETT, K., DUFFY, S. W., WARDLE, J., WALLER, J. and JANES, S. M., 2020. Lung Screen Uptake Trial (LSUT): Randomized Controlled Clinical Trial Testing Targeted Invitation Materials: Am J Respir Crit Care Med Am J Respir Crit Care Med. 201(8), 965-975
• PERROTTA, F., NANKIVELL, M., ADIZIE, J. B., MAQSOOD, U., ELSHAFI, M., JAFRI, S., LERNER, A. D., WOOLHOUSE, I., MUNAVVAR, M., EVISON, M., BOOTON, R., BALDWIN, D. R., JANES, S. M., KERR, K. M., BIANCO, A., YARMUS, L. and NAVANI, N., 2020. Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing in Non-small Cell Lung Cancer: Chest Chest. 158(3), 1230-1239
• RUPAREL, M., QUAIFE, S. L., DICKSON, J. L., HORST, C., TISI, S., HALL, H., TAYLOR, M., AHMED, A., SHAW, P., BURKE, S., SOO, M. J., NAIR, A., DEVARAJ, A., SENNETT, K., DUFFY, S. W., NAVANI, N., BHOWMIK, A., BALDWIN, D. R. and JANES, S. M., 2020. Lung Screen Uptake Trial: results from a single lung cancer screening round: Thorax Thorax. 75(10), 908-912
• RUPAREL, M., QUAIFE, S. L., DICKSON, J. L., HORST, C., TISI, S., HALL, H., TAYLOR, M. N., AHMED, A., SHAW, P. J., BURKE, S., SOO, M. J., NAIR, A., DEVARAJ, A., SENNETT, K., HURST, J. R., DUFFY, S. W., NAVANI, N., BHOWMIK, A., BALDWIN, D. R. and JANES, S. M., 2020. Prevalence, Symptom Burden, and Underdiagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort: Ann Am Thorac Soc Ann Am Thorac Soc. 17(7), 869-878
• VERONESI, G., BALDWIN, D. R., HENSCHKE, C. I., GHISLANDI, S., IAVICOLI, S., OUDKERK, M., DE KONING, H. J., SHEMESH, J., FIELD, J. K., ZULUETA, J. J., HORGAN, D., FIESTAS NAVARRETE, L., INFANTE, M. V., NOVELLIS, P., MURRAY, R. L., PELED, N., RAMPINELLI, C., ROCCO, G., RZYMAN, W., SCAGLIOTTI, G. V., TAMMEMAGI, M. C., BERTOLACCINI, L., TRIPHURIDET, N., YIP, R., ROSSI, A., SENAN, S., FERRANTE, G., BRAIN, K., VAN DER AALST, C., BONOMO, L., CONSONNI, D., VAN MEERBEECK, J. P., MAISONNEUVE, P., NOVELLO, S., DEVARAJ, A., SAGHIR, Z. and PELOSI, G., 2020. Recommendations for Implementing Lung Cancer Screening with Low-Dose Computed Tomography in Europe: Cancers (Basel) Cancers (Basel). 12(6),
• OKE JL, PICKUP LC, DECLERCK J, CALLISTER ME, BALDWIN D, GUSTAFSON J, PESCHL H, ATHER S, TSAKOK M, EXELL A and GLEESON F, 2019. Development and validation of clinical prediction models to risk stratify patients presenting with small pulmonary nodules: a research protocol. Diagnostic and prognostic research. 2, 22
• RICH A, BECKETT P and BALDWIN D, 2019. Status of Lung Cancer Data Collection in Europe. JCO clinical cancer informatics. 2, 1-12
• RUPAREL M, QUAIFE S, BALDWIN D, WALLER J and JANES S, 2019. Defining the information needs of lung cancer screening participants: a qualitative study. BMJ open respiratory research. 6(1), e000448
• RUPAREL M, QUAIFE SL, DICKSON JL, HORST C, BURKE S, TAYLOR M, AHMED A, SHAW P, SOO MJ, NAIR A, DEVARAJ A, O'DOWD EL, BHOWMIK A, NAVANI N, SENNETT K, DUFFY SW, BALDWIN DR, SOFAT R, PATEL RS, HINGORANI A and JANES SM, 2019. Evaluation of cardiovascular risk in a lung cancer screening cohort. Thorax. 74(12), 1140-1146
• BAYMAN N, APPEL W, ASHCROFT L, BALDWIN DR, BATES A, DARLISON L, EDWARDS JG, EZHIL V, GILLIGAN D, HATTON M, JEGANNATHEN A, MANSY T, PEAKE MD, PEMBERTON L, RINTOUL RC, SNEE M, RYDER WD, TAYLOR P and FAIVRE-FINN C, 2019. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37(14), 1200-1208
• SOO E, EDEY AJ, MAK SM, MOSER J, MOHAMMADI S, RODRIGUES T, DUFFY SW, FIELD JK, BALDWIN DR, NAIR A and DEVARAJ A, 2019. Impact of choice of volumetry software and nodule management guidelines on recall rates in lung cancer screening. European journal of radiology. 120, 108646
• RUPAREL M, QUAIFE SL, GHIMIRE B, DICKSON JL, BHOWMIK A, NAVANI N, BALDWIN DR, DUFFY S, WALLER J and JANES SM, 2019. Impact of a Lung Cancer Screening Information Film on Informed Decision-making: A Randomized Trial. Annals of the American Thoracic Society. 16(6), 744-751
• MOFFAT J, HIOM S, KUMAR HS and BALDWIN DR, 2018. Lung cancer screening - gaining consensus on next steps - proceedings of a closed workshop in the UK. Lung cancer (Amsterdam, Netherlands). 125, 121-127
• RICH AL, BALDWIN DR, BECKETT P, BERGHMANS T, BOYD J, FAIVRE-FINN C, GALATEAU-SALLE F, GAMARRA F, GRIGORIU B, HANSEN NG, HARDAVELLA G, JAKOBSEN E, JOVANOVIC D, KONSOULOVA A, MASSARD G, MCPHELIM J, MEERT AP, MILROY R, MUTTI L, PAESMANS M, PEAKE MD, PUTORA PM, DE RUYSSCHER DKM, SCULIER JP, SCHERPEREEL A, SUBOTIC DR, VAN SCHIL P and BLUM TG, 2018. ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe. The European respiratory journal. 52(6),
• FIELD JK, DUFFY SW and BALDWIN DR, 2018. Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial. Translational lung cancer research. 7(Suppl 2), S114-S116
• FIELD JK, BALDWIN DR, DEVARAJ A and OUDKERK M, 2018. EUPS-argues that lung cancer screening should be implemented in 18 months. The British journal of radiology. 91(1090), 20180243
• JONES GS and BALDWIN DR, 2018. Recent advances in the management of lung cancer. Clinical medicine (London, England). 18(Suppl 2), s41-s46
• RICH A, BALDWIN D, ALFAGEME I, BECKETT P, BERGHMANS T, BRINCAT S, BURGHUBER O, CORLATEANU A, CUFER T, DAMHUIS R, DANILA E, DOMAGALA-KULAWIK J, ELIA S, GAGA M, GOKSEL T, GRIGORIU B, HILLERDAL G, HUBER RM, JAKOBSEN E, JONSSON S, JOVANOVIC D, KAVCOVA E, KONSOULOVA A, LAISAAR T, MAKITARO R, MEHIC B, MILROY R, MOLDVAY J, MORGAN R, NANUSHI M, PAESMANS M, PUTORA PM, SAMARZIJA M, SCHERPEREEL A, SCHLESSER M, SCULIER JP, SKRICKOVA J, SOTTO-MAYOR R, STRAND TE, VAN SCHIL P and BLUM TG, 2018. Achieving Thoracic Oncology data collection in Europe: a precursor study in 35 Countries. BMC cancer. 18(1), 1144
• JONES GS, MCKEEVER TM, HUBBARD RB, KHAKWANI A and BALDWIN DR, 2018. Factors influencing treatment selection and 30-day mortality after chemotherapy for people with small-cell lung cancer: An analysis of national audit data. European journal of cancer (Oxford, England : 1990). 103, 176-183
• HIOM SC, KUMAR HS, SWANTON C, BALDWIN DR and PEAKE MD, 2018. Lung cancer in the UK: addressing geographical inequality and late diagnosis. The Lancet. Oncology. 19(8), 1015-1017
• PEAKE MD, NAVANI N and BALDWIN DR, 2018. The continuum of screening and early detection, awareness and faster diagnosis of lung cancer. Thorax. 73(12), 1097-1098
• BALDWIN D, CALLISTER M, AKRAM A, CANE P, DRAFFAN J, FRANKS K, GLEESON F, GRAHAM R, MALHOTRA P, PEARSON P, SUBESINGHE M, WALLER D and WOOLHOUSE I, 2018. British Thoracic Society quality standards for the investigation and management of pulmonary nodules. BMJ open respiratory research. 5(1), e000273
• MØLLER H, COUPLAND VH, TATARU D, PEAKE MD, MELLEMGAARD A, ROUND T, BALDWIN DR, CALLISTER MEJ, JAKOBSEN E, VEDSTED P, SULLIVAN R and SPICER J, 2018. Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients. Thorax. 73(6), 530-537
• FIELD JK, HEUVELMANS MA, DEVARAJ A, HEUSSEL CP, BALDWIN DR, VLIEGENTHART R, DUFFY SW and OUDKERK M, 2018. Low-dose CT for lung cancer screening - Authors' reply. The Lancet. Oncology. 19(3), e135-e136
• HIOM, SARA C., KUMAR, HARPAL S., SWANTON, CHARLES, BALDWIN, DAVID R. and PEAKE, MICHAEL D., 2018. Lung cancer in the UK: addressing geographical inequality and late diagnosis LANCET ONCOLOGY. 19(8), 1015-1017
• NAIR, ARJUN, DEVARAJ, ANAND, CALLISTER, MATTHEW E. J. and BALDWIN, DAVID R., 2018. The Fleischner Society 2017 and British Thoracic Society 2015 guidelines for managing pulmonary nodules: keep calm and carry on THORAX. 73(9), 806-812
• AWAN S, CROSBY V, POTTER V, HENNIG I, BALDWIN D, NDLOVU M, PARADINE S and WILCOCK A, 2017. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. Lung cancer (Amsterdam, Netherlands). 104, 75-78
• OUDKERK M, DEVARAJ A, VLIEGENTHART R, HENZLER T, PROSCH H, HEUSSEL CP, BASTARRIKA G, SVERZELLATI N, MASCALCHI M, DELORME S, BALDWIN DR, CALLISTER ME, BECKER N, HEUVELMANS MA, RZYMAN W, INFANTE MV, PASTORINO U, PEDERSEN JH, PACI E, DUFFY SW, DE KONING H and FIELD JK, 2017. European position statement on lung cancer screening. The Lancet. Oncology. 18(12), e754-e766
• BALDWIN DR and CALLISTER MEJ, 2017. Physician Assessment of Pretest Probability of Malignancy and Adherence to Guidelines for Pulmonary Nodule Evaluation. Chest. 152(2), 447-448
• POWELL HA and BALDWIN DR, 2017. Treatment recommendations for stage I non-small cell lung cancer: does patient preference matter? Annals of translational medicine. 5(20), 411
• WOZNITZA N, DEVARAJ A, JANES SM, DUFFY SW, BHOWMIK A, ROWE S, PIPER K, MAUGHN S and BALDWIN DR, 2017. Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway (radioX): study protocol for a randomised control trial. Trials. 18(1), 521
• NAIR A, SCREATON NJ, HOLEMANS JA, JONES D, CLEMENTS L, BARTON B, GARTLAND N, DUFFY SW, BALDWIN DR, FIELD JK, HANSELL DM and DEVARAJ A, 2017. The impact of trained radiographers as concurrent readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial. European radiology. 28(1), 226-234
• O'DOWD EL and BALDWIN DR, 2017. Lung cancer screening-low dose CT for lung cancer screening: recent trial results and next steps. The British journal of radiology. 20170460
• DEVARAJ A, VAN GINNEKEN B, NAIR A and BALDWIN D, 2017. Use of Volumetry for Lung Nodule Management: Theory and Practice. Radiology. 284(3), 630-644
• SCHMIDT-HANSEN M, BERENDSE S, HAMILTON W and BALDWIN DR, 2017. Lung cancer in symptomatic patients presenting in primary care: a systematic review of risk prediction tools. The British journal of general practice : the journal of the Royal College of General Practitioners. 67(659), e396-e404
• FIELD, J. K., ZULUETA, J., VERONESI, G., OUDKERK, M., BALDWIN, D. R., HOLST PEDERSEN, J., PACI, E., HORGAN, D. and DE KONING, H. J., 2017. EU Policy on Lung Cancer CT Screening 2017: Biomedicine Hub Biomedicine Hub. 2(suppl 1)(Suppl. 1), 10-10
• O'DOWD, E. L., LUCHTENBORG, M., BALDWIN, D. R., MCKEEVER, T. M., POWELL, H. A., MOLLER, H., JAKOBSEN, E. and HUBBARD, R. B., 2016. Predicting death from surgery for lung cancer: A comparison of two scoring systems in two European countries: Lung Cancer Lung Cancer. 95, 88-93
• WALKER AJ, BALDWIN DR, CARD TR, POWELL HA, HUBBARD RB and GRAINGE MJ, 2016. Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data. British journal of cancer. 115(1), 115-21
• BALDWIN DR, 2016. Socioeconomic position and delays in lung cancer diagnosis: should we target the more deprived? Thorax. (In Press.)
• SNEE MP, MCPARLAND L, COLLINSON F, LOWE CM, STRIHA A, BALDWIN DR, NAIDU B, SEBAG-MONTEFIORE D, GREGORY WM, BESTALL J, HEWISON J, HINSLEY S and FRANKS KN, 2016. Erratum to: The SABRTooth feasibility trial protocol: a study to determine the feasibility and acceptability of conducting a phase III randomised controlled trial comparing stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I non-small cell lung cancer (NSCLC) considered to be at higher risk of complications from surgical resection. Pilot and feasibility studies. 2, 55
• BALDWIN DR, DUFFY SW, DEVARAJ A and FIELD JK, 2016. Optimum low dose CT screening interval for lung cancer: the answer from NELSON? Thorax. 72(1), 6-7
• FIELD JK, DUFFY SW, DEVARAJ A and BALDWIN DR, 2016. Implementation planning for lung cancer screening: five major challenges. The Lancet. Respiratory medicine. 4(9), 685-7
• O'DOWD EL, MCKEEVER TM, BALDWIN DR and HUBBARD RB, 2016. Place of Death in Patients with Lung Cancer: A Retrospective Cohort Study from 2004-2013. PloS one. 11(8), e0161399
• BALDWIN DR and CALLISTER ME, 2016. What is the Optimum Screening Strategy for the Early Detection of Lung Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 28(11), 672-681
• NAIR A, GARTLAND N, BARTON B, JONES D, CLEMENTS L, SCREATON NJ, HOLEMANS JA, DUFFY SW, FIELD JK, BALDWIN DR, HANSELL DM and DEVARAJ A, 2016. Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial. The British journal of radiology. 89(1066), 20160301
• MAK KS, VAN BOMMEL AC, STOWELL C, ABRAHM JL, BAKER M, BALDOTTO CS, BALDWIN DR, BORTHWICK D, CARBONE DP, CHEN AB, FOX J, HASWELL T, KOCZYWAS M, KOZOWER BD, MEHRAN RJ, SCHRAMEL FM, SENAN S, STIRLING RG, VAN MEERBEECK JP, WOUTERS MW, PEAKE MD and , 2016. Defining a standard set of patient-centred outcomes for lung cancer. The European respiratory journal. 48(3), 852-60
• BALDWIN DR and DEVARAJ A, 2016. Lung cancer risk in new pulmonary nodules: implications for CT screening and nodule management. The Lancet. Oncology. 17(7), 849-50
• FIELD JK, DUFFY SW, BALDWIN DR, BRAIN KE, DEVARAJ A, EISEN T, GREEN BA, HOLEMANS JA, KAVANAGH T, KERR KM, LEDSON M, LIFFORD KJ, MCRONALD FE, NAIR A, PAGE RD, PARMAR MK, RINTOUL RC, SCREATON N, WALD NJ, WELLER D, WHYNES DK, WILLIAMSON PR, YADEGARFAR G and HANSELL DM, 2016. The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer. Health technology assessment (Winchester, England). 20(40), 1-146
• QUAIFE SL, RUPAREL M, BEEKEN RJ, MCEWEN A, ISITT J, NOLAN G, SENNETT K, BALDWIN DR, DUFFY SW, JANES SM and WARDLE J, 2016. The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and 'hard-to-reach' patients. BMC cancer. 16, 281
• RUPAREL M, QUAIFE SL, NAVANI N, WARDLE J, JANES SM and BALDWIN DR, 2016. Pulmonary nodules and CT screening: the past, present and future. Thorax. 71(4), 367-75
• BAYMAN N, ARDRON D, ASHCROFT L, BALDWIN DR, BOOTON R, DARLISON L, EDWARDS JG, LANG-LAZDUNSKI L, LESTER JF, PEAKE M, RINTOUL RC, SNEE M, TAYLOR P, LUNT C and FAIVRE-FINN C, 2016. Protocol for PIT: a phase III trial of prophylactic irradiation of tracts in patients with malignant pleural mesothelioma following invasive chest wall intervention. BMJ open. 6(1), e010589
• GRAHAM RN, BALDWIN DR, CALLISTER ME and GLEESON FV, 2016. Return of the pulmonary nodule: the radiologist's key role in implementing the 2015 BTS guidelines on the investigation and management of pulmonary nodules. The British journal of radiology. 89(1059), 20150776
• RICH AL, KHAKWANI A, FREE CM, TATA LJ, STANLEY RA, PEAKE MD, HUBBARD RB and BALDWIN DR, 2015. Non-small cell lung cancer in young adults: presentation and survival in the English National Lung Cancer Audit. QJM : monthly journal of the Association of Physicians. 108(11), 891-897
• E O'DOWD, T MCKEEVER, D BALDWIN, S ANWAR, H POWELL, J GIBSON, B IYEN-OMOFOMAN and R HUBBARD, 2015. Author's response: What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK? Thorax. 70(2), 185
• POWELL HA, JONES LL, BALDWIN DR, DUFFY JP, HUBBARD RB, TOD AM, TATA LJ, SOLOMON J and BAINS M, 2015. Patients' attitudes to risk in lung cancer surgery: A qualitative study. Lung cancer (Amsterdam, Netherlands). 90(2), 358-63
• CALLISTER ME and BALDWIN DR, 2015. How should pulmonary nodules be optimally investigated and managed? Lung cancer (Amsterdam, Netherlands). 91, 48-55
• FIELD JK, DEVARAJ A, DUFFY SW and BALDWIN DR, 2015. CT screening for lung cancer: Is the evidence strong enough? Lung cancer (Amsterdam, Netherlands). 91, 29-35
• FIELD JK, DUFFY SW, BALDWIN DR, WHYNES DK, DEVARAJ A, BRAIN KE, EISEN T, GOSNEY J, GREEN BA, HOLEMANS JA, KAVANAGH T, KERR KM, LEDSON M, LIFFORD KJ, MCRONALD FE, NAIR A, PAGE RD, PARMAR MK, RASSL DM, RINTOUL RC, SCREATON NJ, WALD NJ, WELLER D, WILLIAMSON PR, YADEGARFAR G and HANSELL DM, 2015. UK Lung Cancer RCT Pilot Screening Trial: baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening. Thorax. 71(2), 161-70
• BALDWIN DR, CALLISTER ME, GRAHAM R, GLEESON F and , 2015. Pulmonary nodules again? The 2015 British Thoracic Society guidelines on the investigation and management of pulmonary nodules. Clinical radiology. 71(1), 18-22
• BALDWIN DR, 2015. Development of Guidelines for the Management of Pulmonary Nodules: Toward Better Implementation. Chest. 148(6), 1365-7
• JONES GS and BALDWIN DR, 2015. Lung cancer screening and management. Minerva medica. 106(6), 339-54
• RAKHA E, PAJARES MJ, ILIE M, PIO R, ECHEVESTE J, HUGHES E, SOOMRO I, LONG E, IDOATE MA, WAGNER S, LANCHBURY JS, BALDWIN DR, HOFMAN P and MONTUENGA LM, 2015. Stratification of resectable lung adenocarcinoma by molecular and pathological risk estimators. European journal of cancer (Oxford, England : 1990). 51(14), 1897-903
• AWWAD A, TIWARI S, SOVANI V, BALDWIN DR and KUMARAN M, 2015. Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis. BMJ open respiratory research. 2(1), e000075
• ALI N, LIFFORD KJ, CARTER B, MCRONALD F, YADEGARFAR G, BALDWIN DR, WELLER D, HANSELL DM, DUFFY SW, FIELD JK and BRAIN K, 2015. Barriers to uptake among high-risk individuals declining participation in lung cancer screening: a mixed methods analysis of the UK Lung Cancer Screening (UKLS) trial. BMJ open. 5(7), e008254
• BALDWIN DR, CALLISTER ME and , 2015. The British Thoracic Society guidelines on the investigation and management of pulmonary nodules. Thorax. 70(8), 794-8
• CALLISTER ME, BALDWIN DR, AKRAM AR, BARNARD S, CANE P, DRAFFAN J, FRANKS K, GLEESON F, GRAHAM R, MALHOTRA P, PROKOP M, RODGER K, SUBESINGHE M, WALLER D, WOOLHOUSE I, and , 2015. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 70 Suppl 2, ii1-ii54
• BALDWIN DR, 2015. Prediction of risk of lung cancer in populations and in pulmonary nodules: Significant progress to drive changes in paradigms. Lung cancer (Amsterdam, Netherlands). 89(1), 1-3
• SCHMIDT-HANSEN M, BALDWIN DR and ZAMORA J, 2015. FDG-PET/CT imaging for mediastinal staging in patients with potentially resectable non-small cell lung cancer. Jama. 313(14), 1465-6
• NAVANI N, NANKIVELL M, LAWRENCE DR, LOCK S, MAKKER H, BALDWIN DR, STEPHENS RJ, PARMAR MK, SPIRO SG, MORRIS S, JANES SM and , 2015. Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label, pragmatic, randomised controlled trial. The Lancet. Respiratory medicine. 3(4), 282-9
• O'DOWD EL, MCKEEVER TM, BALDWIN DR, ANWAR S, POWELL HA, GIBSON JE, IYEN-OMOFOMAN B and HUBBARD RB, 2015. Author's response: What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK? Thorax. 70(2), 185
• O'DOWD EL and BALDWIN DR, 2015. Early diagnosis pivotal to survival in lung cancer. The Practitioner. 258(1776), 21-4, 2-3
• POWELL HA, TATA LJ, BALDWIN DR, POTTER VA, STANLEY RA, KHAKWANI A and HUBBARD RB, 2014. Treatment decisions and survival for people with small-cell lung cancer. British journal of cancer. 110(4), 908-915
• BALDWIN DR, 2014. Effective lung cancer screening is possible. BMJ (Clinical research ed.). 348, g363
• FIELD JK, ABERLE DR, ALTORKI N, BALDWIN DR, DRESLER C, DUFFY SW, GOLDSTRAW P, HIRSCH FR, PEDERSEN JH, DE KONING HJ, MULSHINE JL, SULLIVAN DC, TSAO M, TRAVIS WD and INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER STRATEGIC SCREENING ADVISORY COMMITTEE, 2014. The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) Response to the USPSTF Recommendations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 9(2), 141-3
• MCRONALD FE, YADEGARFAR G, BALDWIN DR, DEVARAJ A, BRAIN KE, EISEN T, HOLEMANS JA, LEDSON M, SCREATON NJ, RINTOUL RC, HANDS CJ, LIFFORD K, WHYNES DK, KERR KM, PAGE R, PARMAR M, WALD N, WELLER D, WILLIAMSON PR, MYLES J, HANSELL DM, DUFFY SW and FIELD JK, 2014. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer prevention research (Philadelphia, Pa.).
• KHAKWANI A, RICH AL, TATA LJ, POWELL HA, STANLEY RA, BALDWIN DR and HUBBARD RB, 2014. Small-cell lung cancer in England: trends in survival and chemotherapy using the national lung cancer audit. PloS one. 9(2), e89426
• BALDWIN DR, HANSELL DM, DUFFY SW and FIELD JK, 2014. Lung cancer screening with low dose computed tomography. BMJ (Clinical research ed.). 348, g1970
• BLUM TG, RICH A, BALDWIN D, BECKETT P, DE RUYSSCHER D, FAIVRE-FINN C, GAGA M, GAMARRA F, GRIGORIU B, HANSEN NCG, HUBBARD R, HUBER RM, JAKOBSEN E, JOVANOVIC D, KONSOULOVA A, KOLLMEIER J, MASSARD G, MCPHELIM J, MEERT A, MILROY R, PAESMANS M, PEAKE M, PUTORA P, SCHERPEREEL A, SCHÖNFELD N, SITTER H, SKAUG K, SPIRO S, STRAND T, TARIGHT S, THOMAS M, VAN SCHIL PE, VANSTEENKISTE JF, WIEWRODT R and SCULIER J, 2014. The European initiative for quality management in lung cancer care. The European respiratory journal. 43(5), 1254-77
• KHAKWANI A, RICH AL, POWELL HA, TATA LJ, STANLEY RA, BALDWIN DR, DUFFY JP and HUBBARD RB, 2014. The impact of the 'hub and spoke' model of care for lung cancer and equitable access to surgery. Thorax. 70(2), 146-151
• E O'DOWD and D BALDWIN, 2014. Early diagnosis pivotal to survival in lung cancer Practitioner. 258(1776), 21-4
• D BALDWIN and E O'DOWD, 2014. Next steps and barriers to implementing lung cancer screening with low-dose CT Br J Radiol. 87(1044),
• O'DOWD EL, MCKEEVER TM, BALDWIN DR, ANWAR S, POWELL HA, GIBSON JE, IYEN-OMOFOMAN B and HUBBARD RB, 2014. What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK? Thorax. 70(2), 161-8
• LUECHTENBORG, MARGREET, RIAZ, SHARMA P., LIM, ERIC, PAGE, RICHARD, BALDWIN, DAVID R., JAKOBSEN, ERIK, VEDSTED, PETER, LIND, MIKE, PEAKE, MICHAEL D., MELLEMGAARD, ANDERS, SPICER, JAMES, LANG-LAZDUNSKI, LOIC and MOLLER, HENRIK, 2014. Survival of patients with small cell lung cancer undergoing lung resection in England, 1998-2009 THORAX. 69(3), 269-273
• SCHMIDT-HANSEN M, BALDWIN DR, HASLER E, ZAMORA J, ABRAIRA V and ROQUÉ I FIGULS M, 2014. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. The Cochrane database of systematic reviews. CD009519
• O'DOWD EL, KUMARAN M, ANWAR S, PALOMO B and BALDWIN DR, 2014. Brain metastases following radical surgical treatment of non-small cell lung cancer: is preoperative brain imaging important? Lung cancer (Amsterdam, Netherlands). 86(2), 185-9
• CHINUCK R, DEWAR J, BALDWIN DR and HENDRON E, 2014. Appetite stimulants for people with cystic fibrosis. The Cochrane database of systematic reviews. CD008190
• KHAKWANI A, RICH AL, TATA LJ, POWELL HA, STANLEY RA, BALDWIN DR and HUBBARD RB, 2013. The pathological confirmation rate of lung cancer in England using the NLCA database. Lung cancer (Amsterdam, Netherlands). 79(2), 125-31
• POWELL HA, IYEN-OMOFOMAN B, HUBBARD RB, BALDWIN DR and TATA LJ, 2013. The association between smoking quantity and lung cancer in men and women. Chest. 143(1), 123-9
• POWELL HA, IYEN-OMOFOMAN B, BALDWIN DR, HUBBARD RB and TATA LJ, 2013. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 8(1), 6-11
• IYEN-OMOFOMAN, B., TATA, L.J., BALDWIN, D.R., SMITH, C.J.P. and HUBBARD, R.B., 2013. Using socio-demographic and early clinical features in general practice to identify people with lung cancer earlier Thorax. 68(5), 451-459
• POWELL, H.A., TATA, L.J., BALDWIN, D.R., STANLEY, R.A., KHAKWANI, A. and HUBBARD, R.B., 2013. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit Thorax. 68(9), 826-834
• KHAKWANI A, RICH AL, POWELL HA, TATA LJ, STANLEY RA, BALDWIN DR, DUFFY JP and HUBBARD RB, 2013. Lung cancer survival in England: trends in non-small-cell lung cancer survival over the duration of the National Lung Cancer Audit. British journal of cancer. (In Press.)
• POWELL HA, IYEN-OMOFOMAN B, BALDWIN DR, HUBBARD RB and TATA LJ, 2013. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 8(4), e34-5
• FIELD JK, HANSELL DM, DUFFY SW and BALDWIN DR, 2013. CT screening for lung cancer: countdown to implementation. The lancet oncology. 14(13), e591-600
• FIELD JK, BALDWIN D, BRAIN K, DEVARAJ A, EISEN T, DUFFY SW, HANSELL DM, KERR K, PAGE R, PARMAR M, WELLER D, WHYNES D and WILLIAMSON P, 2013. Authors' response. Thorax. 68(1), 105
• NAIR A, BALDWIN DR, FIELD JK, HANSELL DM and DEVARAJ A, 2012. Measurement methods and algorithms for the management of solid nodules. Journal of thoracic imaging. 27(4), 230-9
• BALDWIN DR, 2012. The (US) National Lung Cancer Screening Trial: intensifying the debate about the introduction of screening for lung cancer. The journal of the Royal College of Physicians of Edinburgh. 42(2), 131-2
• SCHMIDT-HANSEN M, BALDWIN DR and HASLER E, 2012. What is the most effective follow-up model for lung cancer patients? A systematic review. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 7(5), 821-4
• FIELD JK, SMITH RA, ABERLE DR, OUDKERK M, BALDWIN DR, YANKELEVITZ D, PEDERSEN JH, SWANSON SJ, TRAVIS WD, WISBUBA II, NOGUCHI M, MULSHINE JL and IASLC CT SCREENING WORKSHOP 2011 PARTICIPANTS, 2012. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 7(1), 10-9
• RICH, A.L., TATA, L.J., FREE, C.M., STANLEY, R.A., PEAKE, M.D., BALDWIN, D.R. and HUBBARD, R.B., 2011. How do patient and hospital features influence outcomes in small-cell lung cancer in England? British Journal of Cancer. 105(6), 746-752
• RICH, A.L., TATA, L.J., FREE, C.M., STANLEY, R.A., PEAKE, M.D., BALDWIN, D.R. and HUBBARD, R.B., 2011. Inequalities in outcomes for non-small cell lung cancer: the influence of clinical characteristics and features of the local lung cancer service Thorax. 66(12), 1078-1084
• BALDWIN DR, 2011. Improving outcomes in lung cancer patients. The Practitioner. 255(1745), 19-22, 2
• BALDWIN DR, WHITE B, SCHMIDT-HANSEN M, CHAMPION AR, MELDER AM and GUIDELINE DEVELOPMENT GROUP, 2011. Diagnosis and treatment of lung cancer: summary of updated NICE guidance. BMJ (Clinical research ed.). 342, d2110
• BALDWIN DR, 2011. Imaging in lung cancer: recent advances in PET-CT and screening. Thorax. 66(4), 275-7
• RICH, ANNA L, TATA, LAILA J, STANLEY, ROSAMUND A, FREE, CATHERINE M, PEAKE, MICHAEL D, BALDWIN, DAVID R and HUBBARD, RICHARD B, 2010. Lung cancer in England: Information from the National Lung Cancer Audit (LUCADA). Lung cancer (Amsterdam, Netherlands).
• HUBBARD RB and BALDWIN DR, 2010. Diagnosing Lung Cancer Earlier In The Uk. Thorax. 65(9), 756-8
• BALDWIN, D. R., DUFFY, S. W., WALD, N. J., PAGE, R., HANSELL, D. M. and FIELD, J. K., 2010. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer THORAX. 66(4), 308-313
• CHAUHAN, ALPNA, SIDDALL, VANESSA, WILCOCK, ANDREW, MALLAWATHANTRI, SUGAMYA, BALDWIN, DAVID R and JOHNSTON, IAN D, 2007. NICE guidance for screening for malnutrition: implications for lung cancer services. Thorax. 62(9), 835
• CHINUCK, R.S., FORTNUM, H. and BALDWIN, D.R., 2007. Appetite stimulants in cystic fibrosis: a systematic review. Journal of Human Nutrition and Dietetics. 20(6), 526-37
• FREE CM, ELLIS M, BEGGS L, BEGGS D, MORGAN SA and BALDWIN DR, 2007. Lung cancer outcomes at a UK cancer unit between 1998-2001. Lung cancer (Amsterdam, Netherlands). 57(2), 222-8
• LEWIS NR, LE JEUNE I and BALDWIN DR, 2005. Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway. British journal of cancer. 93(8), 905-8
• ZIGLAM HM, BALDWIN DR, DANIELS I, ANDREW JM and FINCH RG, 2002. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. The Journal of antimicrobial chemotherapy. 50(6), 1011-5
• BALDWIN DR, GANNON P, BRIGHT P, NEWTON DT, ROBERTSON A, VENABLES K, GRANEEK B, BARKER RD, CARTIER A, MALO J, WILSHER M, PANTIN CFA and BURGE PS, 2002. Interpretation of occupational peak flow records: level of agreement between expert clinicians and Oasys-2. Thorax. 57(10), 860-4
• BALDWIN DR, EATON T, KOLBE J, CHRISTMAS T, MILNE D, MERCER J, STEELE E, GARRETT J, WILSHER ML and WELLS AU, 2002. Management of solitary pulmonary nodules: how do thoracic computed tomography and guided fine needle biopsy influence clinical decisions? Thorax. 57(9), 817-22
• RODGERS HC, BALDWIN DR and KNOX AJ, 2000. Questionnaire survey of male infertility in cystic fibrosis. Respiratory medicine. 94(10), 1002-3
• BURGE PS, PANTIN CF, NEWTON DT, GANNON PF, BRIGHT P, BELCHER J, MCCOACH J, BALDWIN DR and BURGE CB, 1999. Development of an expert system for the interpretation of serial peak expiratory flow measurements in the diagnosis of occupational asthma. Midlands Thoracic Society Research Group. Occupational and environmental medicine. 56(11), 758-64
• LIM WS, MACFARLANE JT, DEEGAN PC, MANHIRE A, HOLMES WF and BALDWIN DR, 1999. How do general practitioners respond to reports of abnormal chest X-rays? Journal of the Royal Society of Medicine. 92(9), 446-9
• CLIFF IJ, EVANS AH, PANTIN CF and BALDWIN DR, 1999. Comparison of two new methods for the measurement of lung volumes with two standard methods. Thorax. 54(4), 329-33
• BALDWIN DR, KOLBE J, TROY K, BELCHER J, GIBBS H, FRANKEL A, EATON T, CHRISTMAS T and VEALE A, 1998. Comparative clinical and physiological features of Maori, Pacific Islanders and Europeans with sleep related breathing disorders. Respirology (Carlton, Vic.). 3(4), 253-60
• LAMONT J, BALDWIN DR, HAY KD and VEALE AG, 1998. Effect of two types of mandibular advancement splints on snoring and obstructive sleep apnoea. European journal of orthodontics. 20(3), 293-7
• BALDWIN DR, BEECH CA, EVANS AH, PRESCOTT J, BRADBURY SP and PANTIN CF, 1997. Principals of design and evaluation of an information system for a department of respiratory medicine. Health care analysis : HCA : journal of health philosophy and policy. 5(1), 78-84
• BALDWIN DR and ALLEN MB, 1997. Non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. BMJ (Clinical research ed.). 314(7075), 163-4
• BALDWIN DR, LAMBERT L, PANTIN CF, PROWSE K and COLE RB, 1996. Silicosis presenting as bilateral hilar lymphadenopathy. Thorax. 51(11), 1165-7
• BALDWIN DR, 1996. The penetration of novel intravenous cephalosporins into the lung. Journal of chemotherapy (Florence, Italy). 8 Suppl 2, 71-82
• BALDWIN DR, BATES AJ, EVANS AH, BRADBURY SP and PANTIN CF, 1995. Nocturnal oxygen desaturation and exercise-induced desaturation in subjects with chronic obstructive pulmonary disease. Respiratory medicine. 89(9), 599-601
• ANDREWS JM, WISE R, BALDWIN DR and HONEYBOURNE D, 1995. Concentrations of ceftibuten in plasma and the respiratory tract following a single 400 mg oral dose. International journal of antimicrobial agents. 5(2), 141-4
• PANTIN CF, KING R, PATHAK U, BALDWIN DR, BURGE PS and CUSHLEY MJ, 1995. Treating asthma. Scoring system developed for drug related morbidity. BMJ (Clinical research ed.). 310(6974), 255
• BALDWIN DR, SIVARDEEN Z, PAVORD ID and KNOX AJ, 1994. Comparison of the effects of salbutamol and adrenaline on airway smooth muscle contractility in vitro and on bronchial reactivity in vivo. Thorax. 49(11), 1103-8
• HONEYBOURNE D, GREAVES I, BALDWIN DR, ANDREWS JM, HARRIS M and WISE R, 1994. The concentration of sparfloxacin in lung tissues after single and multiple oral doses. International journal of antimicrobial agents. 4(3), 151-5
• BALDWIN DR, HILL AL, PECKHAM DG and KNOX AJ, 1994. Effect of addition of exercise to chest physiotherapy on sputum expectoration and lung function in adults with cystic fibrosis. Respiratory medicine. 88(1), 49-53
• KNOX AJ, BALDWIN DR, CRAGOE EJ and AJAO P, 1993. The effect of sodium transport and calcium channel inhibitors on phorbol ester-induced contraction of bovine airway smooth muscle. Pulmonary pharmacology. 6(4), 241-6
• BALDWIN DR, WISE R, ANDREWS JM, GILL M and HONEYBOURNE D, 1993. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration. Respiratory medicine. 87(8), 595-601
• BALDWIN DR, BALFOUR T and KNOX AJ, 1993. Laparoscopic cholecystectomy in patients with cystic fibrosis. Respiratory medicine. 87(3), 223-4
• BALDWIN DR, GRANGE KL, PAVORD I and KNOX AJ, 1992. The effect of amiloride on the airway response to metabisulphite in asthma: a negative report. The European respiratory journal. 5(10), 1189-92
• BALDWIN DR, ANDREWS JM, WISE R and HONEYBOURNE D, 1992. Bronchoalveolar distribution of cefuroxime axetil and in-vitro efficacy of observed concentrations against respiratory pathogens. The Journal of antimicrobial chemotherapy. 30(3), 377-85
• HONEYBOURNE D and BALDWIN DR, 1992. The site concentrations of antimicrobial agents in the lung. The Journal of antimicrobial chemotherapy. 30(3), 249-60
• BALDWIN DR, WISE R, ANDREWS JM and HONEYBOURNE D, 1992. Concentrations of cefpodoxime in serum and bronchial mucosal biopsies. The Journal of antimicrobial chemotherapy. 30(1), 67-71
• BALDWIN DR, WISE R, ANDREWS JM and HONEYBOURNE D, 1992. Quantitative morphology and water distribution of bronchial biopsy samples. Thorax. 47(7), 504-7
• BALDWIN DR, HONEYBOURNE D and WISE R, 1992. Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrobial agents and chemotherapy. 36(6), 1176-80
• BALDWIN DR, HONEYBOURNE D and WISE R, 1992. Pulmonary disposition of antimicrobial agents: methodological considerations. Antimicrobial agents and chemotherapy. 36(6), 1171-5
• BALDWIN DR, WISE R, ANDREWS JM, ASHBY JP and HONEYBOURNE D, 1992. The distribution of temafloxacin in bronchial epithelial lining fluid, alveolar macrophages and bronchial mucosa. The European respiratory journal. 5(4), 471-6
• WISE R, BALDWIN DR, ANDREWS JM and HONEYBOURNE D, 1991. Comparative pharmacokinetic disposition of fluoroquinolones in the lung. The Journal of antimicrobial chemotherapy. 28 Suppl C, 65-71
• BALDWIN DR, WISE R, ANDREWS JM and HONEYBOURNE D, 1991. Microlavage: a technique for determining the volume of epithelial lining fluid. Thorax. 46(9), 658-62
• COOPER MA, ANDREWS JM, BALDWIN DR, THORNBER D and WISE R, 1991. In-vitro activity and beta-lactamase stability of SR 44337, a new long acting cephalosporin. The Journal of antimicrobial chemotherapy. 28(2), 229-37
• BALDWIN DR, MAXWELL SR, HONEYBOURNE D, ANDREWS JM, ASHBY JP and WISE R, 1991. The penetration of cefpirome into the potential sites of pulmonary infection. The Journal of antimicrobial chemotherapy. 28(1), 79-86
• BALDWIN DR, BERG JD, BUCKLEY BM and MACKAY AD, 1991. Theophylline analysis at the chest clinic--comparison of a portable versus conventional system. Respiratory medicine. 85(1), 21-5
• BALDWIN DR, WISE R, ANDREWS JM, ASHBY JP and HONEYBOURNE D, 1990. Azithromycin concentrations at the sites of pulmonary infection. The European respiratory journal. 3(8), 886-90
• BALDWIN DR, HONEYBOURNE D, ANDREWS JM, ASHBY JP and WISE R, 1990. Concentrations of oral lomefloxacin in serum and bronchial mucosa. Antimicrobial agents and chemotherapy. 34(6), 1017-9
• BALDWIN DR, WILKINSON L, ANDREWS JM, ASHBY JP, WISE R and HONEYBOURNE D, 1990. Concentrations of temafloxacin in serum and bronchial mucosa. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 9(6), 432-4
• CHADHA D, WISE R, BALDWIN DR, ANDREWS JM, ASHBY JP and HONEYBOURNE D, 1990. Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose. The Journal of antimicrobial chemotherapy. 25(6), 959-63
• BALDWIN DR, ANDREWS JM, ASHBY JP, WISE R and HONEYBOURNE D, 1990. Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax. 45(5), 401-2
• BALDWIN DR, ORMEROD LP, MACKAY AD and STABLEFORTH DE, 1990. Changes in hospital management of acute severe asthma by thoracic and general physicians in Birmingham and Manchester during 1978 and 1985. Thorax. 45(2), 130-4